Therapeutic use of anti-CS1 antibodies
View Patent ↗The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
1. An isolated anti-CS1 antibody or antigen binding fragment which binds to a protein encoded by SEQ ID NO:1 and comprises a heavy chain variable region comprising heavy chain CDRs of SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17 and a light chain variable region comprising light chain CDRs of SEQ ID NO:18, SEQ ID NO:19, and SEQ ID NO:20.
2. The isolated anti-CS1 antibody or antigen binding fragment of claim 1 in which the heavy chain variable region comprises SEQ ID NO:5.
3. The isolated anti-CS1 antibody or antigen binding fragment of claim 2 in which the light chain variable region comprises SEQ ID NO:6.
4. An isolated anti-CS1 antibody or antigen binding fragment which binds to a protein encoded by SEQ ID NO:1 and comprises a heavy chain variable region comprising heavy chain CDRs of SEQ ID NO:15, SEQ ID NO:87, and SEQ ID NO: 17 and a light chain variable region comprising light chain CDRs of SEQ ID NO:18, SEQ ID NO:19, and SEQ ID NO:20.
5. The isolated anti-CS1 antibody or antigen binding fragment of claim 4 in which the heavy chain variable region comprises SEQ ID NO:41.
6. The isolated anti-CS1 antibody or antigen binding fragment of claim 5 in which the light chain variable region comprises SEQ ID NO:44.
7. A conjugate compound comprising the isolated anti-CS1 antibody or antigen binding fragment of claim 1 or claim 4 conjugated to a cytotoxic agent.
8. A pharmaceutical composition comprising the conjugate compound of claim 7 and an acceptable carrier.
9. The isolated anti-CS1 antibody or antigen binding fragment of claim 1 which is a monoclonal antibody.
10. The isolated anti-CS1 antibody or antigen binding fragment of claim 1 which is a humanized antibody.
11. The isolated anti-CS1 antibody or antigen binding fragment of claim 1 which is an IgG 1 .
12. The isolated anti-CS1 antibody or antigen binding fragment of claim 4 which is a monoclonal antibody.
13. The isolated anti-CS1 antibody or antigen binding fragment of claim 4 which is a humanized antibody.
14. The isolated anti-CS1 antibody or antigen binding fragment of claim 4 which is an IgG 1 .
15. The isolated anti-CS1 antibody or antigen binding fragment of claim 5 which is a monoclonal antibody.
16. The isolated anti-CS1 antibody or antigen binding fragment of claim 5 which is a humanized antibody.
17. The isolated anti-CS1 antibody or antigen binding fragment of claim 5 which is an IgG 1 .
18. The isolated anti-CS1 antibody or antigen binding fragment of claim 6 which is a monoclonal antibody.
19. The isolated anti-CS1 antibody or antigen binding fragment of claim 6 which is a humanized antibody.
20. The isolated anti-CS1 antibody or antigen binding fragment of claim 6 which is an IgG 1 .
21. The isolated anti-CS1 antibody or antigen binding fragment of claim 20 which is an IgG 1 .
22. A pharmaceutical composition comprising the isolated anti-CS1 antibody or antigen binding fragment of anyone of claims 1 to 3 , 4 to 6 and 9 to 21 , and an acceptable carrier.
23. A method of treating a plasma cell cancer, comprising administering to a patient in need thereof the pharmaceutical composition of claim 22 .
24. The method of claim 23 wherein the plasma cell cancer is multiple myeloma.
25. A method of treating a plasma cell cancer, comprising administering to a patient in need thereof the isolated anti-CS1 antibody or antigen binding fragment of any one of claims 1 to 3 , 4 to 6 , and 9 to 21 .
26. The method of claim 25 wherein the plasma cell cancer is multiple myeloma.